You call that $82 superior value and you willing to surrender your shares?
The execs. make their money and common shareholders make theirs as well b/c of the excellent job done by the execs.
For Exec. compensations, please also check out Yahoo's Exec.'s pay check.
Talk about cheap, now I know who's shopping in the 99c store - Teva.
Show your mola and I'll be convinced.
Some saying money talks and................
One thing is obvious that Mylan do not want to merge with Teva, Mr.Coury's attitute and strategy is to force the hands of Teva, unless Teva willing to pay up and satisfying the big institutional shareholders then there will be no sale, pay up or shut up Teva.
So call jacka## now he is sitting on the bargaining table, trying hard to make money for everyone including you IMO.
Can't argue with a $22 profit. Mylan now keep increase the acquiring price of Prgo. in certain point these two may sitting down and agree on something IMO. As for Teva everything to them is always three steps behind, bad and slow management decisions.
Mylan's stand alone as someone on this board indicated value at $121.
Coury do not want a sell to Teva below the current value, the potential of a merger with prgo will tensely increases Mylan's earning power maybe into the $5-6 range, persuing Prgo is Coury's goal.
To merge with Prgo is the best thing can happen for all shareholders of Myl long term.
For Teva pay up or shut up.
Since Mylan firmly want to rid of Teva, Prgo will have a good time to raise the value of its holdings i.e. Mylan have to pay them excessively than in s normal merger. Coury now been pinched in a corner, to him Prgo is a must have and the time is the essence.
So Coury is right at it, well over $100 to the negotiate point with Teva.
At this point, Teva is conducting a consensual view of the institution share holders, selling point could be around $95-100 IMO.
Wrong, arrogance is not a crime but confidence. I assume that you have bot the MYL shares and luckily has a guy like Coury to look after your value. North of $100 is just a fair value for MYL's growth and earning power, it will entertain 100 no later than the middle of next year Teva or not.
You maybe just too anxious to turn in a profit, The profits you make here obviously come by the management team's due diligences which Mr.Coury is a leader.
My believe is Teva will bid for Perrigo too, since they will integrate better than an unwillingness MYL.
I do think the poison pill did MYL some damage, however if we look forward, without Perrigo Mylan still will grow past $100.
MYL knows they are the bullseye of the industry. Now they are playing hardball, whatever who want to get involved must pay a greater price for Myl. Days reckoning: within a year.
Sentiment: Strong Buy